SEPN

Septerna, Inc. Common Stock
SEPN
Market cap $450M

10.17 USD

-0.24

2.31%

At close Jun 13, 4:00 PM EDT

After hours

10.11

-0.06

0.59%

1 day

-2.31%

5 days

-1.26%

1 month

51.11%

3 months

59.15%

6 months

-54.58%

Year to date

-52.37%

1 year

-52.48%

5 years

-52.48%

10 years

-52.48%

About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Employees: 75

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

2.52% more ownership

Funds ownership: 99.39% [Q4 2024] → 101.91% (+2.52%) [Q1 2025]

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 71 [Q4 2024] → 71 (+0) [Q1 2025]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]

65% less call options, than puts

Call options by funds: $157K | Put options by funds: $444K

74% less capital invested

Capital invested by funds: $1.01B [Q4 2024] → $262M (-$748M) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

77%

upside

Avg. target

$22

111%

upside

High target

$25

146%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Cantor Fitzgerald Josh Schimmer	146%upside $25	Overweight Maintained	16 May 2025
Wells Fargo Derek Archila	77%upside $18	Equal-Weight Maintained	16 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about SEPN published over the past 30 days

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.

Septerna to Present at Jefferies Global Healthcare Conference

Analysts Think These Stocks Could More Than Double in Value

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.

Analysts Think These Stocks Could More Than Double in Value

Zacks Investment Research

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require additional funding, potentially diluting current shareholders.

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Zacks Investment Research

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Zacks Investment Research

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

Proactive Investors

Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies

Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and metabolic disease therapies, which include the injectables Wegovy and Ozempic.

Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Septerna Inc. SEPN and Novo Nordisk A/S NVO announced an exclusive global collaboration and license agreement on Wednesday.

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

See News Rankings

Charts implemented using Lightweight Charts™